Welcome to our dedicated page for BELLEROPHON THERPETCS news (Ticker: BLPH), a resource for investors and traders seeking the latest updates and insights on BELLEROPHON THERPETCS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BELLEROPHON THERPETCS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BELLEROPHON THERPETCS's position in the market.
Bellerophon Therapeutics has appointed Naseem Amin, M.D. as the new Chairman of its Board of Directors, effective immediately, following the retirement of Jonathan Peacock. Dr. Amin has been an Independent Director since 2015 and brings extensive experience in the biotech sector, serving as CEO at Orphalan and previously holding leadership roles at Arix Bioscience and Biogen Idec. His appointment comes during a pivotal time for Bellerophon, which is advancing its INOpulse® platform for treating pulmonary hypertension patients.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) provided a clinical update and first-quarter financial results for 2021. The Company is advancing its INOpulse inhaled nitric oxide therapy, with ongoing enrollment in the pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease (fILD) patients. Bellerophon reported a net loss of $5.5 million, or $(0.58) per share, for Q1 2021, compared to a net loss of $5.0 million, or $(1.08) per share, in Q1 2020. The Company’s cash and cash equivalents stood at $39.7 million as of March 31, 2021.
Bellerophon Therapeutics (Nasdaq: BLPH) reported a net loss of $8.0 million for Q4 2020 and $24.7 million for the entire year, reflecting increased R&D expenses related to clinical trials. The Company announced the enrollment of the first patient in its Phase 3 REBUILD study for fibrotic interstitial lung disease and expects top-line results from its Phase 2 study in sarcoidosis in 2021. Despite the financial losses, Bellerophon maintains a strong cash position of $47.6 million as of December 31, 2020, allowing continued support for ongoing clinical programs.
Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting March 9, 2021, on the company’s website. Bellerophon focuses on developing innovative therapies for cardiopulmonary and infectious diseases, including its proprietary INOpulse® program, a pulsatile nitric oxide delivery system. For more information, visit bellerophon.com.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 on the Company’s website. Bellerophon focuses on developing therapies for cardiopulmonary and infectious diseases, particularly through its proprietary INOpulse® nitric oxide delivery system.
Bellerophon Therapeutics (Nasdaq: BLPH) announced the enrollment of the first patient in the REBUILD Phase 3 clinical study, evaluating INOpulse® for fibrotic interstitial lung disease (fILD). This randomized, double-blind trial aims to assess the safety and efficacy of pulsed inhaled nitric oxide in 300 patients. The primary endpoint focuses on changes in moderate to vigorous physical activity. The study builds on positive results from a Phase 2 trial, which showed significant improvements in physical activity and quality of life metrics for patients receiving INOpulse.
Bellerophon Therapeutics (BLPH) announced a clinical hold on its Phase 3 COViNOX study of INOpulse® for COVID-19 following an interim analysis of the first 100 patients. The Data Monitoring Committee found 10 events of respiratory failure or death, indicating a limited sample size. Meanwhile, the company is optimistic about its fibrotic interstitial lung disease (fILD) program and plans to initiate the Phase 3 REBUILD study soon. Ongoing trials for pulmonary hypertension are progressing, with results expected by the end of 2020.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 3:30 PM ET. This clinical-stage biotherapeutics company focuses on innovative treatments for cardiopulmonary and infectious diseases, including its proprietary INOpulse® nitric oxide delivery system. The presentation will be accessible through a live audio webcast on the company’s website.
Bellerophon Therapeutics (BLPH) provided an update on its clinical programs and third-quarter financial results for 2020. The company is advancing its INOpulse inhaled nitric oxide therapy, currently evaluating it in the COViNOX Phase 3 trial for COVID-19, with results from an interim analysis expected soon. Additionally, the REBUILD Phase 3 study for fibrotic interstitial lung disease has initiated patient enrollment. Financially, Bellerophon reported a net loss of $7.9 million for Q3 2020, up from $4.3 million in Q3 2019, while expenses increased due to development activities. The company holds $54 million in cash as of September 30, 2020.
Bellerophon Therapeutics (Nasdaq: BLPH) has announced the presentation of data from its Phase 2 clinical study (iNO-PF) concerning the use of INOpulse® for fibrotic Interstitial Lung Disease patients prone to pulmonary hypertension. The findings will be showcased at notable events, including the American Thoracic Society Interstitial Lung Disease Mini Symposia and the 2020 Pulmonary Fibrosis Foundation Meeting on November 5, 2020. This research highlights the potential impact of inhaled nitric oxide therapy in improving patient outcomes.
FAQ
What is the current stock price of BELLEROPHON THERPETCS (BLPH)?
What is the market cap of BELLEROPHON THERPETCS (BLPH)?
